Phase I study of BAY 73-4506, an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors: Final results of a dose-escalation study

被引:0
|
作者
Frost, A.
Buechert, M.
Unger, C.
Christensen, O.
Wagner, A.
Heinig, R. A.
Scheulen, M. E.
Strumberg, D.
Fasol, U.
Mross, K.
机构
[1] Tumor Biol Ctr, Freiburg, Germany
[2] Univ Hosp Freiburg, Freiburg, Germany
[3] Bayer HealthCare Pharmaceut, West Haven, CT USA
[4] Bayer Schering Pharma AG, Berlin, Germany
[5] Bayer HealthCare, Wuppertal, Germany
[6] Univ Essen Gesamthsch, Sch Med, Essen, Germany
[7] Univ Hosp Bochum, Marienhosp Herne, Herne, Germany
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
2558
引用
收藏
页数:1
相关论文
共 50 条
  • [31] A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors
    de Braud, F.
    Cascinu, S.
    Spitaleri, G.
    Pilz, K.
    Clementi, L.
    Liu, D.
    Sikken, P.
    De Pas, T.
    ANNALS OF ONCOLOGY, 2015, 26 (11) : 2341 - 2346
  • [32] Phase I dose-escalation study of brostallicin in combination with cisplatin (cDDP) in patients with advanced solid tumors
    Lorusso, D.
    Fornari, G.
    Caponigro, F.
    Quirino, M.
    Merlano, M.
    Airoldi, M.
    Schena, M.
    Jannuzzo, M. G.
    Crippa, S.
    Scambia, G.
    EJC SUPPLEMENTS, 2007, 5 (04): : 111 - 112
  • [33] Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors
    A. Craig Lockhart
    Shankar Sundaram
    John Sarantopoulos
    Monica M. Mita
    Andrea Wang-Gillam
    Jennifer L. Moseley
    Stephanie L. Barber
    Alex R. Lane
    Claudine Wack
    Laurent Kassalow
    Jean-François Dedieu
    Alain C. Mita
    Investigational New Drugs, 2014, 32 : 1236 - 1245
  • [34] Phase I dose-escalation study of volasertib in pediatric patients with acute leukemia or advanced solid tumors
    Doz, Francois
    Locatelli, Franco
    Baruchel, Andre
    Blin, Nicolas
    De Moerloose, Barbara
    Frappaz, Didier
    Dworzak, Michael
    Fischer, Matthias
    Stary, Jan
    Fuertig, Rene
    Riemann, Kathrin
    Taube, Tillmann
    Reinhardt, Dirk
    PEDIATRIC BLOOD & CANCER, 2019, 66 (10)
  • [35] A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
    Jeffrey R. Infante
    Roger B. Cohen
    Kevin B. Kim
    Howard A. Burris
    Gregory Curt
    Ugochi Emeribe
    Delyth Clemett
    Helen K. Tomkinson
    Patricia M. LoRusso
    Investigational New Drugs, 2017, 35 : 576 - 588
  • [36] Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors
    Lockhart, A. Craig
    Sundaram, Shankar
    Sarantopoulos, John
    Mita, Monica M.
    Wang-Gillam, Andrea
    Moseley, Jennifer L.
    Barber, Stephanie L.
    Lane, Alex R.
    Wack, Claudine
    Kassalow, Laurent
    Dedieu, Jean-Francois
    Mita, Alain C.
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (06) : 1236 - 1245
  • [37] Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors
    Isambert, Nicolas
    Freyer, Gilles
    Zanetta, Sylvie
    You, Benoit
    Fumoleau, Pierre
    Falandry, Claire
    Favier, Laure
    Assadourian, Sylvie
    Soussan-Lazard, Karen
    Ziti-Ljajic, Samira
    Trillet-Lenoir, Veronique
    CLINICAL CANCER RESEARCH, 2012, 18 (06) : 1743 - 1750
  • [38] A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
    LoRusso, Patricia M.
    Infante, Jeffrey R.
    Kim, Kevin B.
    Burris, Howard A., III
    Curt, Gregory
    Emeribe, Ugochi
    Clemett, Delyth
    Tomkinson, Helen K.
    Cohen, Roger B.
    BMC CANCER, 2017, 17
  • [39] A phase I dose-escalation and pk study of continuous oral rucaparib in patients with advanced solid tumors
    Flynn, M.
    Shapiro, G.
    LoRusso, P.
    Kristeleit, R.
    Patel, M.
    Infante, J.
    Giordano, H.
    Borrow, J.
    Jaw-Tsai, S.
    Burris, H., III
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S185 - S185
  • [40] A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
    Patricia M. LoRusso
    Jeffrey R. Infante
    Kevin B. Kim
    Howard A. Burris
    Gregory Curt
    Ugochi Emeribe
    Delyth Clemett
    Helen K. Tomkinson
    Roger B. Cohen
    BMC Cancer, 17